JOINN Laboratories has successfully completed several toxicology programs for different biologics including bi-specific antibodies, antibody-drug conjugates (ADCs), fusion proteins, peptides, vaccines and cell and gene therapies.
JOINN Laboratories has partnered with multiple US and EU based biotech and pharmaceutical companies at its multiple facilities that meet international standards (GMP, GLP and GCP). The facilities use multiple small and large animal models including rats, mice, hamsters and ferrets as well as primates and swine. JOINN clients have the benefits of a wide range of disease and pharmacology animal models, expedited study start times and budget-friendly pricing.
JOINN Laboratories offers a comprehensive portfolio of end-to-end preclinical drug discovery and development services.
JOINN Biologics is a CRO/CDMO focused on biological modalities including monoclonal antibodies and antibody derivatives. The end-to-end service portfolio ranges from antibody discovery and optimization to scaled manufacturing and support services. Visit JOINN Biologics
JOINN Laboratories is the largest public nonclinical CRO in China with facilities in non-clinical and clinical facilities in Beijing, Suzhou and Chongqing, and a non-clinical facility in Guangzhou. Additionally, there are 3 dedicated Lab Animal and Models sites in Wuzhou, Yunnan and Nanning. JOINN Laboratories has successfully completed multiple accreditations and certification including AAALAC accreditation and US FDA GLP inspection. The company expanded into the US with sites in Richmond CA and Worcester MA to serve the major biotech hubs. U.S. East and West Coasts in major biotech hubs.
JOINN Laboratories has grown to over 2,500 employees worldwide and the core team includes experienced executives who have an average of 25 year experience in the drug development and regulatory review areas.
